166 related articles for article (PubMed ID: 32201920)
1. Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer.
Alhuseinalkhudhur A; Lubberink M; Lindman H; Tolmachev V; Frejd FY; Feldwisch J; Velikyan I; Sörensen J
EJNMMI Res; 2020 Mar; 10(1):21. PubMed ID: 32201920
[TBL] [Abstract][Full Text] [Related]
2. Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.
Sörensen J; Velikyan I; Sandberg D; Wennborg A; Feldwisch J; Tolmachev V; Orlova A; Sandström M; Lubberink M; Olofsson H; Carlsson J; Lindman H
Theranostics; 2016; 6(2):262-71. PubMed ID: 26877784
[TBL] [Abstract][Full Text] [Related]
3. Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.
Sandberg D; Tolmachev V; Velikyan I; Olofsson H; Wennborg A; Feldwisch J; Carlsson J; Lindman H; Sörensen J
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1337-1346. PubMed ID: 28261749
[TBL] [Abstract][Full Text] [Related]
4. Human Epidermal Growth Factor Receptor 2-Targeting [
Alhuseinalkhudhur A; Lindman H; Liss P; Sundin T; Frejd FY; Hartman J; Iyer V; Feldwisch J; Lubberink M; Rönnlund C; Tolmachev V; Velikyan I; Sörensen J
J Nucl Med; 2023 Sep; 64(9):1364-1370. PubMed ID: 37442602
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients.
Sandström M; Lindskog K; Velikyan I; Wennborg A; Feldwisch J; Sandberg D; Tolmachev V; Orlova A; Sörensen J; Carlsson J; Lindman H; Lubberink M
J Nucl Med; 2016 Jun; 57(6):867-71. PubMed ID: 26912439
[TBL] [Abstract][Full Text] [Related]
6. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule.
Sörensen J; Sandberg D; Sandström M; Wennborg A; Feldwisch J; Tolmachev V; Åström G; Lubberink M; Garske-Román U; Carlsson J; Lindman H
J Nucl Med; 2014 May; 55(5):730-5. PubMed ID: 24665085
[TBL] [Abstract][Full Text] [Related]
7. Parametric Net Influx Rate Images of
Ilan E; Sandström M; Velikyan I; Sundin A; Eriksson B; Lubberink M
J Nucl Med; 2017 May; 58(5):744-749. PubMed ID: 27789716
[No Abstract] [Full Text] [Related]
8. Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [
Altena R; Burén SA; Blomgren A; Karlsson E; Tzortzakakis A; Brun N; Moein MM; Jussing E; Frejd FY; Bergh J; Tran TA; Hartman J; Axelsson R
J Nucl Med; 2024 May; 65(5):700-707. PubMed ID: 38548353
[TBL] [Abstract][Full Text] [Related]
9. A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue.
Tolmachev V; Velikyan I; Sandström M; Orlova A
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1356-67. PubMed ID: 20130858
[TBL] [Abstract][Full Text] [Related]
10. Optimized, automated and cGMP-compliant synthesis of the HER2 targeting [
Jussing E; Ferrat M; Moein MM; Alfredéen H; Tegnebratt T; Bratteby K; Samén E; Feldwisch J; Altena R; Axelsson R; Tran TA
EJNMMI Radiopharm Chem; 2023 Nov; 8(1):41. PubMed ID: 37991639
[TBL] [Abstract][Full Text] [Related]
11. Comparison of tracer kinetic models for
Smith NJ; Green MA; Bahler CD; Tann M; Territo W; Smith AM; Hutchins GD
EJNMMI Res; 2024 Jan; 14(1):6. PubMed ID: 38198060
[TBL] [Abstract][Full Text] [Related]
12. Impact of
Zhou N; Liu C; Guo X; Xu Y; Gong J; Qi C; Zhang X; Yang M; Zhu H; Shen L; Yang Z
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):161-175. PubMed ID: 32564171
[TBL] [Abstract][Full Text] [Related]
13. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
14. Application of a Novel
Miao H; Sun Y; Jin Y; Hu X; Song S; Zhang J
Front Oncol; 2022; 12():894767. PubMed ID: 35712499
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic HER2-binding radiopharmaceutical, [
Velikyan I; Schweighöfer P; Feldwisch J; Seemann J; Frejd FY; Lindman H; Sörensen J
Am J Nucl Med Mol Imaging; 2019; 9(1):12-23. PubMed ID: 30911434
[TBL] [Abstract][Full Text] [Related]
16. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules.
Baum RP; Prasad V; Müller D; Schuchardt C; Orlova A; Wennborg A; Tolmachev V; Feldwisch J
J Nucl Med; 2010 Jun; 51(6):892-7. PubMed ID: 20484419
[TBL] [Abstract][Full Text] [Related]
17. Multiparametric dynamic whole-body PSMA PET/CT using [
Dias AH; Jochumsen MR; Zacho HD; Munk OL; Gormsen LC
EJNMMI Res; 2023 Apr; 13(1):31. PubMed ID: 37060394
[TBL] [Abstract][Full Text] [Related]
18. First results on kinetic modelling and parametric imaging of dynamic
Sari H; Mingels C; Alberts I; Hu J; Buesser D; Shah V; Schepers R; Caluori P; Panin V; Conti M; Afshar-Oromieh A; Shi K; Eriksson L; Rominger A; Cumming P
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1997-2009. PubMed ID: 34981164
[TBL] [Abstract][Full Text] [Related]
19. Comparison between a dual-time-window protocol and other simplified protocols for dynamic total-body
Wang Z; Wu Y; Li X; Bai Y; Chen H; Ding J; Shen C; Hu Z; Liang D; Liu X; Zheng H; Yang Y; Zhou Y; Wang M; Sun T
EJNMMI Phys; 2022 Sep; 9(1):63. PubMed ID: 36104580
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Tracer Kinetic Models for 68Ga-PSMA-11 PET in Intermediate Risk Primary Prostate Cancer Patients.
Smith NJ; Green MA; Bahler CD; Tann M; Territo W; Smith AM; Hutchins GD
Res Sq; 2023 Nov; ():. PubMed ID: 37961116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
